An excellent paper that highlights the potential use of AlveoGene's InGenuITy®️ unique inhaled gene therapy platform. It provides a very firm foundation for risk mitigation and successful clinical translation of our AVG-002, AVG-003, and AVG-001 assets indication in lethal neonatal surfactant protein deficiencies SP-B, ABCA3 and AATD lung disease respectively.
Our manuscript “Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial” has just been fully published in American Journal of Respiratory and Critical Care Medicine (https://lnkd.in/eG377qS7).